Module 1 - Background on Bispecific Antibodies and CAR-T Therapies
Primary Audience:
This activity is intended to meet the educational needs of emergency department clinicians.
In this module, we’ll build a foundation of knowledge about bispecific antibodies and CAR T-cell therapies—their indications, mechanisms, and typical adverse events.
Syed Abbas Ali, MBBS
Assistant Professor or Oncology
Department of Oncology, Hematologic Malignancies
Johns Hopkins School of Medicine
Baltimore, MD
Dr. Syed Abbas Ali is a medical oncology specialist in Baltimore, caring for patients with cancer.
Dr. Ali earned his M.B.B.S. at The Aga Khan University. He completed his residency at the University of Arkansas for Medical Sciences and performed a fellowship in medical oncology at the National Institutes of Health.
1.
Identify the common adverse events seen with bispecific antibodies and CAR T therapies that would present in the emergency department setting.
